Compounded Ozempic is a version of semaglutide, the active ingredient in Ozempic, that is mixed and prepared by a compounding pharmacy rather than manufactured by Novo Nordisk, the company that makes the brand-name drug. These compounded versions became widely available starting in 2022, when surging demand for semaglutide created a nationwide shortage. As of February 2025, the FDA declared that shortage resolved, which significantly changes the legal landscape for compounded semaglutide.
How Compounded Semaglutide Differs From Ozempic
Brand-name Ozempic comes in pre-filled injection pens at standardized doses, manufactured under strict FDA oversight. Compounded semaglutide, by contrast, is typically prepared as a liquid in a vial that you draw into a syringe yourself. The medication is mixed by a pharmacist using bulk semaglutide powder rather than being produced on a pharmaceutical manufacturing line.
A critical distinction involves the form of semaglutide used. Some compounding pharmacies have used salt forms of the drug, specifically semaglutide sodium or semaglutide acetate, rather than the semaglutide base found in FDA-approved products. The FDA has stated clearly that these salt forms are different active ingredients and that the agency has no information on whether they behave the same way in the body. The FDA is also not aware of any lawful basis for using these salt forms in compounding.
Many compounding pharmacies also add other ingredients to their semaglutide formulations. Vitamin B12 is one of the most common additions. The rationale is that semaglutide slows digestion and reduces stomach acid, which can interfere with B12 absorption over time. Adding B12 to the injection may help prevent a deficiency while also supporting energy levels, since fatigue is a common complaint during semaglutide therapy. Some formulations include other compounds like L-carnitine, though clinical evidence supporting these combinations is limited.
Why Compounded Versions Became So Common
Federal law allows pharmacies to compound copies of FDA-approved drugs under specific circumstances, one of which is when the brand-name product is listed on the FDA’s official drug shortage database. Semaglutide injection products were listed as being in shortage from 2022 through early 2025, driven by enormous demand for both diabetes management and weight loss. During that window, compounding pharmacies could legally prepare semaglutide without the usual prohibition against copying commercially available drugs.
Two types of pharmacies operate under this framework. Traditional compounding pharmacies, regulated under Section 503A of federal law, fill patient-specific prescriptions. Outsourcing facilities, regulated under Section 503B, can produce larger batches without individual prescriptions. Both types were permitted to compound semaglutide during the shortage period.
The Shortage Is Over: What That Means
In February 2025, the FDA determined that the semaglutide injection shortage was resolved, confirming with Novo Nordisk that manufacturing capacity could meet current and projected national demand. This is a major shift, because once a drug is no longer in shortage, compounding pharmacies generally lose the legal basis to produce copies of it.
To avoid abruptly cutting off patients mid-treatment, the FDA set transition windows. State-licensed pharmacies compounding under Section 503A had until April 22, 2025, to stop compounding, distributing, or dispensing semaglutide. Outsourcing facilities operating under Section 503B had until May 22, 2025. After those dates, compounding semaglutide as a copy of an approved product is no longer permitted under the shortage exemption. The FDA noted it may still take enforcement action at any time if products are found to be of substandard quality or otherwise unsafe.
Patients and prescribers may still encounter occasional, localized supply disruptions as products move through the distribution chain from manufacturer to local pharmacies, but these are expected to be temporary.
Safety Concerns With Compounded Semaglutide
Compounded medications do not go through the same testing and approval process as brand-name drugs. There is no requirement for clinical trials proving that a compounded version works identically to the original, and the FDA does not verify the safety or effectiveness of compounded products before they reach patients.
Sterility is a particular concern for injectable medications. Reputable compounding pharmacies follow preparation standards set by USP General Chapter 797, which covers contamination prevention, correct dosing, and proper handling for sterile products. These standards became officially effective in November 2023. However, not all pharmacies follow them rigorously, and enforcement varies by state.
Beyond compounding pharmacies, counterfeit Ozempic products have also entered the U.S. supply chain. The FDA has warned about fake Ozempic pens with counterfeit labels, packaging, and patient information. In seized counterfeit products, even the sterility of the included needles could not be confirmed, creating infection risk on top of uncertainty about what was actually in the pen.
How to Tell if a Compounding Pharmacy Is Legitimate
The National Association of Boards of Pharmacy offers a compounding pharmacy accreditation that verifies compliance with federal 503A requirements and applicable USP standards. To earn this accreditation, a pharmacy must hold current, active licenses in every state where it operates, have a licensed pharmacist in charge of operations, pass a facility inspection, and demonstrate compliance with USP chapters covering sterile compounding (797), nonsterile compounding (795), and hazardous drug handling (800) as applicable.
If you’ve been using compounded semaglutide, you can verify your pharmacy’s credentials through NABP’s website. The pharmacy should also be able to tell you exactly which form of semaglutide it uses and whether any additional ingredients are included in the formulation. A pharmacy that cannot or will not answer those questions is a red flag.
Cost and Access Differences
The main reason compounded semaglutide grew so popular, beyond the shortage itself, was price. Brand-name Ozempic and Wegovy carry list prices that can exceed $1,000 per month without insurance, and many insurance plans restrict or deny coverage, particularly for weight loss. Compounded versions were typically available at a fraction of that cost, making semaglutide accessible to people who otherwise couldn’t afford it.
With the shortage now resolved and the compounding window closing, patients who relied on compounded semaglutide for cost reasons face a difficult transition. The brand-name products remain expensive, and insurance coverage remains inconsistent. If you’re in this situation, talking with your prescriber about alternatives, manufacturer savings programs, or other weight management options is a practical next step.